Available Technologies

Browse Penn-owned technologies available for licensing.

HOME SEARCH RSS FEED

Targeted drug delivery using red-blood cells for transport

Platform technology for targeted drug delivery using red blood cells for transport. 

Problem: 

Drug delivery can often result in up to 99% of the drug being delivered to off-target organs. This can lead to side-effects and toxicities. Current methods that bind drugs to red-blood cells for transport can require modifying the structure of the red blood cell. 

Solution: 

A platform technology for targeted drug delivery to target organs while reducing off target drug effects. This platform technology can be used with a variety of small molecule drugs required for treating organ sites without modifying the structure of the red blood cell. 

Technology Overview: 

Liposomes have been engineered to display antibodies that target red-blood cells and specific organ-sites, allowing for dual targeting. The liposomes can be loaded with a variety of small molecule drugs. Binding the liposome loaded with the drug molecule to red blood cells allows for leveraging red blood cells as drug shuttles and carriers.

Advantages: 

  • 2x greater drug delivery to the targeted organ as compared to passive red blood cell binding
  • Control of nanocarrier binding to red blood cell to reduce variability
  • Utilization with a broad range of nanocarriers
  • Increased plasma half-life of nanocarriers

Stage of Development: 

In vivo proof of concept

Intellectual Property: 

Provisional filed 

Desired Partnerships: 

  • License
  • Co-development

Patent Information:

Inventors:

Laura Ferguson
Elizabeth Hood
Carlos Villa
Jacob Brenner
Vladimir Muzykantov

Docket # 20-9162

For Information, Contact:

Jessica Casciano
Licensing Officer, PSOM Licensing Group
University of Pennsylvania
(215) 573-5414
casciano@upenn.edu

Keywords:

Cardiovascular
COVID-19
Drug Delivery
Nanotechnology
Pulmonary